Form 4: Galectin CFO Sells Shares After Option Exercises
Statement of Changes in Beneficial Ownership
Galectin Therapeutics CFO Jack W. Callicutt executed planned stock option exercises and subsequent sales, realizing significant gains.
Summary
- Jack W. Callicutt, Chief Financial Officer of Galectin Therapeutics Inc. (GALT), engaged in multiple transactions involving the company's common stock on November 3 and November 4, 2025.
- These transactions were conducted under a Rule 10b5-1 plan adopted on April 17, 2025.
- On November 3, 2025, Callicutt exercised options to acquire 1,300 shares at $1.98, 1,260 shares at $1.11, and 1,250 shares at $1.72.
- Immediately following these exercises on November 3, 2025, he sold 1,300 shares, 1,260 shares, and 1,250 shares, respectively, at a weighted average price of $6.01 per share.
- On November 4, 2025, Callicutt exercised options to acquire 8,914 shares at $1.98, 8,974 shares at $1.11, and 10,741 shares at $1.72.
- Following these exercises on November 4, 2025, he sold 8,914 shares, 8,974 shares, and 10,741 shares, respectively, at a weighted average price of $6.07 per share.
- The options exercised had various vesting schedules, with some fully vested by December 31, 2023, and others vesting through December 31, 2025.
- Following all reported transactions, Callicutt's direct beneficial ownership of common stock is 7,614 shares.
Sentiment
Score: 7
Explanation: The sentiment is moderately positive for the insider due to significant profits realized from option exercises and sales. For the company, it is neutral as it's a routine insider transaction under a pre-arranged plan.
Positives
- The CFO realized significant profits from exercising stock options at lower prices and selling shares at substantially higher market prices (e.g., exercising at $1.11 and selling at $6.01 or $6.07).
- The transactions were conducted under a pre-arranged Rule 10b5-1 plan, indicating a structured approach to insider trading and reducing concerns about opportunistic selling.
Negatives
- Insider selling, even under a 10b5-1 plan, can sometimes be perceived negatively by investors, as it reduces the insider's direct stake in the company.
Future Outlook
This Form 4 filing does not contain forward-looking statements or guidance regarding the company's future performance or outlook. It solely reports insider transactions.
Management Comments
- The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on April 17, 2025, as disclosed in the Issuer’s Quarterly Report on Form 10-Q, filed with the SEC on August 14, 2025.
Industry Context
This filing is a standard insider transaction report and does not provide information directly related to broader industry trends or competitive landscape. It reflects an individual executive's personal financial planning.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Policy Implementation | The transactions were executed under a Rule 10b5-1 plan, which is a pre-arranged trading plan designed to allow insiders to sell shares without being accused of trading on material non-public information. | 04/17/2025 | This plan enhances corporate governance by providing a structured and transparent framework for insider stock transactions, mitigating potential concerns about opportunistic trading. |
Related Party Transactions
- Jack W. Callicutt, the Chief Financial Officer of Galectin Therapeutics Inc., engaged in transactions involving the company's common stock, which are considered related-party transactions.
Stakeholder Impact
- Shareholders: May note the CFO's decision to sell a portion of his holdings, though the pre-arranged 10b5-1 plan suggests a planned financial move rather than a reaction to new information. The significant profit margin could be viewed positively as an indicator of past stock performance.
Key Dates
| Date | Description |
|---|---|
| 06/30/2022 | First vesting date for some stock options. |
| 12/31/2022 | Second vesting date for some stock options. |
| 06/30/2023 | First vesting date for other stock options and third vesting date for some options. |
| 12/31/2023 | Second vesting date for other stock options and fourth vesting date for some options. |
| 06/30/2024 | Third vesting date for other stock options. |
| 12/31/2024 | Fourth vesting date for other stock options. |
| 04/17/2025 | Date the Rule 10b5-1 plan was adopted by the reporting person. |
| 06/30/2025 | Third vesting date for a set of stock options. |
| 11/03/2025 | Date of earliest reported transactions (option exercises and sales). |
| 11/04/2025 | Date of additional reported transactions (option exercises and sales). |
| 11/05/2025 | Signature date of the reporting person on the Form 4. |
| 12/31/2025 | Scheduled final vesting date for a set of stock options. |
| 01/24/2032 | Expiration date for stock options with an exercise price of $1.98. |
| 01/26/2033 | Expiration date for stock options with an exercise price of $1.11. |
| 01/22/2034 | Expiration date for stock options with an exercise price of $1.72. |
Keywords
Galectin Therapeutics, GALT, Form 4, Insider Trading, Stock Options, CFO, Stock Sale, 10b5-1 Plan, Beneficial Ownership
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.